1887

Journal of General Virology header logo

Volume 105, Issue 11

Increased human herpesvirus-8 neutralizing response during remission from Kaposi’s sarcoma No Access

Abstract

Human herpesvirus-8 (HHV-8), also known as Kaposi’s sarcoma-associated herpesvirus, is a human oncogenic herpesvirus that is responsible for several diseases including Kaposi’s sarcoma (KS). KS prevalence varies dramatically, although emergence increases considerably with human immunodeficiency virus -1 (HIV-1) co-infection, making it one of the most common cancers in HIV-1 patients and sub-Saharan African men, even prior to the HIV-1 epidemic in Africa. Studies have shown that neutralizing antibodies exist in HHV-8-infected sera, which are most likely targeted to viral lytic surface glycoproteins, such as glycoprotein K8.1 (gpK8.1) and gHgL. Fifty-eight HHV-8-positive serum samples were tested for the levels of gpK8.1- and gHgL-binding antibodies and HHV-8-neutralizing capacity. Each sample was then categorized according to the disease status, which included asymptomatic infection, active KS and remission from KS, and the three measured parameters were compared between the disease groups. We show that neutralizing capacity in infected patient sera increases with remission of KS. Interestingly, antibodies targeting gpK8.1, but not gHgL, were also found to be increased during active disease and remission. Comparison of neutralizing capacity and antibody levels on an individual patient basis revealed that antibody levels, primarily targeting gHgL, are correlated with serum neutralizing response in sub-lingual Kaposi sarcoma (SLK) cells. Adsorption of gHgL or gpK8.1 antibodies from human sera removed the neutralizing response in SLK cells, although some non-specific removal of antibodies from the sera means that this result should be interpreted with caution. Taken collectively, these results suggest that glycoproteins, such as gHgL, are targets for neutralizing antibodies. Furthermore, our data imply that recovery from KS is associated with increased neutralizing capacity, suggesting that neutralizing antibodies may contribute to KS resolution. However, it is vital for further work to be completed in order to elucidate this relationship.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): gHgL , gpk8.1 , HHV-8 , Kaposi's sarcoma , neutralizing antibodies and remission
Funding
This study was supported by the:
  • Friedrich-Alexander-Universität Erlangen-Nürnberg
    • Principle Award Recipient: HannahC. Byren
  • Deutsche Forschungsgemeinschaft (Award GRK2504)
    • Principle Award Recipient: FrankNeipel
© 2024 The Authors
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.002044
2024-11-20
2024-12-02
Loading full text...

Full text loading...

References

  1. Grabar S, Costagliola D. Epidemiology of Kaposi’s sarcoma. Cancers 2021; 13:5692 [View Article] [PubMed]
     [Google Scholar]
  2. Cesarman E, Damania B, Krown SE, Martin J, Bower M et al. Kaposi sarcoma. Nat Rev Dis Primers 2019; 5:9 [View Article] [PubMed]
     [Google Scholar]
  3. Chang HH, Ganem D. A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity. Cell Host Microbe 2013; 13:429–440 [View Article]
     [Google Scholar]
  4. Birkmann A, Mahr K, Ensser A, Yağuboğlu S, Titgemeyer F et al. Cell surface heparan sulfate is a receptor for human herpesvirus 8 and interacts with envelope glycoprotein K8.1. J Virol 2001; 75:11583–11593 [View Article]
     [Google Scholar]
  5. Wang FZ, Akula SM, Pramod NP, Zeng L, Chandran B. Human herpesvirus 8 envelope glycoprotein K8.1A interaction with the target cells involves heparan sulfate. J Virol 2001; 75:7517–7527 [View Article] [PubMed]
     [Google Scholar]
  6. Hahn AS, Kaufmann JK, Wies E, Naschberger E, Panteleev-Ivlev J et al. The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi’s sarcoma–associated herpesvirus. Nat Med 2012; 18:961–966 [View Article]
     [Google Scholar]
  7. Nagy S, Gyulai R, Kemeny L, Szenohradszky P, Dobozy A. Iatrogenic Kaposi’s sarcoma: HHV8 positivity persists but the tumors regress almost completely without immunosuppressive therapy. Transplantation 2000; 69:2230–2231 [View Article] [PubMed]
     [Google Scholar]
  8. Wijnveen AC, Persson H, Björck S, Blohmé I. Disseminated Kaposi’s sarcoma--full regression after withdrawal of immunosuppressive therapy: report of a case. Transplant Proc 1987; 19:3735–3736 [PubMed]
     [Google Scholar]
  9. Engels EA, Biggar RJ, Marshall VA, Walters MAKL, Gamache CJ et al. Detection and quantification of Kaposi’s sarcoma-associated herpesvirus to predict AIDS-associated Kaposi’s sarcoma. AIDS 2003; 17:1847–1851 [View Article] [PubMed]
     [Google Scholar]
  10. Lefrère JJ, Meyohas MC, Mariotti M, Meynard JL, Thauvin M et al. Detection of human herpesvirus 8 DNA sequences before the appearance of Kaposi’s sarcoma in human immunodeficiency virus (HIV)-positive subjects with a known date of HIV seroconversion. J Infect Dis 1996; 174:283–287 [View Article] [PubMed]
     [Google Scholar]
  11. Whitby D, Boshoff C, Hatzioannou T, Weiss RA, Schulz TF et al. Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi’s sarcoma. Lancet 1995; 346:799–802 [View Article]
     [Google Scholar]
  12. Nalwoga A, Roshan R, Moore K, Marshall V, Miley W et al. Kaposi’s sarcoma-associated herpesvirus T cell responses in HIV seronegative individuals from rural Uganda. Nat Commun 2021; 12:7323 [View Article] [PubMed]
     [Google Scholar]
  13. Roshan R, Labo N, Trivett M, Miley W, Marshall V et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget 2017; 8:109402–109416 [View Article]
     [Google Scholar]
  14. Pellett PE, Wright DJ, Engels EA, Ablashi DV, Dollard SC et al. Multicenter comparison of serologic assays and estimation of human herpesvirus 8 seroprevalence among US blood donors. Transfusion 2003; 43:1260–1268 [View Article] [PubMed]
     [Google Scholar]
  15. Labo N, Miley W, Marshall V, Gillette W, Esposito D et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog 2014; 10:e1004046 [View Article] [PubMed]
     [Google Scholar]
  16. Bourboulia D, Aldam D, Lagos D, Allen E, Williams I et al. Short- and long-term effects of highly active antiretroviral therapy on Kaposi sarcoma-associated herpesvirus immune responses and viraemia. AIDS 2004; 18:485–493 [View Article]
     [Google Scholar]
  17. Dialyna IA, Graham D, Rezaee R, Blue CE, Stavrianeas NG et al. Anti-HHV-8/KSHV antibodies in infected individuals inhibit infection in vitro. AIDS 2004; 18:1263–1270 [View Article] [PubMed]
     [Google Scholar]
  18. Inoue N, Spira T, Lam L, Corchero JL, Luo W. Comparison of serologic responses between Kaposi’s sarcoma-positive and -negative men who were seropositive for both human herpesvirus 8 and human immunodeficiency virus. J Med Virol 2004; 74:202–206 [View Article] [PubMed]
     [Google Scholar]
  19. Kimball LE, Casper C, Koelle DM, Morrow R, Corey L et al. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis 2004; 189:2016–2022 [View Article] [PubMed]
     [Google Scholar]
  20. Kumar P, Kuwa NY, Minhas V, Marimo C, Shea DM et al. Higher levels of neutralizing antibodies against KSHV in KS patients compared to asymptomatic individuals from Zambia. PLoS One 2013; 8:e71254 [View Article] [PubMed]
     [Google Scholar]
  21. Lidenge SJ, Tso FY, Ngalamika O, Ngowi JR, Mortazavi Y et al. Similar immunological profiles between African endemic and human immunodeficiency virus type 1-associated epidemic Kaposi sarcoma (KS) patients reveal the primary role of KS-associated herpesvirus in KS pathogenesis. J Infect Dis 2019; 219:1318–1328 [View Article] [PubMed]
     [Google Scholar]
  22. Barasa AK, Ye P, Phelps M, Arivudainambi GT, Tison T et al. BALB/c mice immunized with a combination of virus-like particles incorporating Kaposi sarcoma-associated herpesvirus (KSHV) envelope glycoproteins gpK8.1, gB, and gH/gL induced comparable serum neutralizing antibody activity to UV-inactivated KSHV. Oncotarget 2017; 8:34481–34497 [View Article] [PubMed]
     [Google Scholar]
  23. Mulama DH, Mutsvunguma LZ, Totonchy J, Ye P, Foley J et al. A multivalent Kaposi sarcoma-associated herpesvirus-like particle vaccine capable of eliciting high titers of neutralizing antibodies in immunized rabbits. Vaccine 2019; 37:4184–4194 [View Article] [PubMed]
     [Google Scholar]
  24. Mortazavi Y, Lidenge SJ, Tran T, West JT, Wood C et al. The Kaposi’s sarcoma-associated herpesvirus (KSHV) gH/gL complex is the predominant neutralizing antigenic determinant in KSHV-infected individuals. Viruses 2020; 12:256 [View Article] [PubMed]
     [Google Scholar]
  25. Polstra AM, Van Den Burg R, Goudsmit J, Cornelissen M. Human herpesvirus 8 load in matched serum and plasma samples of patients with AIDS-associated Kaposi’s sarcoma. J Clin Microbiol 2003; 41:5488–5491 [View Article] [PubMed]
     [Google Scholar]
  26. Stürzl M, Gaus D, Dirks WG, Ganem D, Jochmann R. Kaposi’s sarcoma-derived cell line SLK is not of endothelial origin, but is a contaminant from a known renal carcinoma cell line. Int J Cancer 2013; 132:1954–1958 [View Article] [PubMed]
     [Google Scholar]
  27. Myoung J, Ganem D. Generation of a doxycycline-inducible KSHV producer cell line of endothelial origin: maintenance of tight latency with efficient reactivation upon induction. J Virol Methods 2011; 174:12–21 [View Article] [PubMed]
     [Google Scholar]
  28. Vieira J, O’Hearn PM. Use of the red fluorescent protein as a marker of Kaposi’s sarcoma-associated herpesvirus lytic gene expression. Virology 2004; 325:225–240 [View Article]
     [Google Scholar]
  29. Wakeham K, Johnston WT, Nalwoga A, Webb EL, Mayanja BN et al. Trends in Kaposi’s sarcoma-associated herpesvirus antibodies prior to the development of HIV-associated Kaposi’s sarcoma: a nested case-control study. Int J Cancer 2015; 136:2822–2830 [View Article] [PubMed]
     [Google Scholar]
  30. Biggar RJ, Engels EA, Whitby D, Kedes DH, Goedert JJ. Antibody reactivity to latent and lytic antigens to human herpesvirus-8 in longitudinally followed homosexual men. J Infect Dis 2003; 187:12–18 [View Article] [PubMed]
     [Google Scholar]
  31. Liu S, Großkopf AK, Yang X, Mannheim ME, Backovic M et al. Kaposi’s sarcoma-associated herpesvirus glycoprotein K8.1 is critical for infection in a cell-specific manner and functions at the attachment step on keratinocytes. J Virol 2023; 97:e0083223 [View Article] [PubMed]
     [Google Scholar]
  32. Dollery SJ, Santiago-Crespo RJ, Chatterjee D, Berger EA. Glycoprotein K8.1A of Kaposi’s sarcoma-associated herpesvirus is a critical B cell tropism determinant independent of its heparan sulfate binding activity. J Virol 2019; 93:1876–18 [View Article] [PubMed]
     [Google Scholar]
  33. Muniraju M, Mutsvunguma LZ, Foley J, Escalante GM, Rodriguez E et al. Kaposi sarcoma-associated herpesvirus glycoprotein H is indispensable for infection of epithelial, endothelial, and fibroblast cell types. J Virol 2019; 93:e00630–19 [View Article]
     [Google Scholar]
  34. Bu W, Joyce MG, Nguyen H, Banh D, Aguilar F et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize epstein-barr virus in B cells and epithelial cells. Immunity 2019; 50:
     [Google Scholar]
  35. Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM et al. Early age at time of primary Epstein-Barr virus infection results in poorly controlled viral infection in infants from Western Kenya: clues to the etiology of endemic Burkitt lymphoma. J Infect Dis 2012; 205:906–913 [View Article] [PubMed]
     [Google Scholar]
  36. Ptaschinski C, Rochford R. Infection of neonates with murine gammaherpesvirus 68 results in enhanced viral persistence in lungs and absence of infectious mononucleosis syndrome. J Gen Virol 2008; 89:1114–1121 [View Article] [PubMed]
     [Google Scholar]
  37. Renwick N, Halaby T, Weverling GJ, Dukers NHTM, Simpson GR et al. Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi’s sarcoma. AIDS 1998; 12:2481–2488 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jgv/10.1099/jgv.0.002044
Loading
Increased human herpesvirus-8 neutralizing response during remission from Kaposi’s sarcoma
J. Gen. Virol. 105, 002044 (2024); https://doi.org/10.1099/jgv.0.002044
/content/journal/jgv/10.1099/jgv.0.002044
/content/journal/jgv/10.1099/jgv.0.002044
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error